Heart Test Labs Granted Nasdaq Compliance Extension

Heart Test Laboratories, Inc. ( (HSCS) ) just unveiled an announcement.

HeartSciences Inc. has been granted an extension by Nasdaq to regain compliance with the minimum stockholders’ equity requirement, with a deadline of September 15, 2025, to complete necessary transactions. Failure to comply could lead to delisting, impacting the company’s stock liquidity and market presence. In the third quarter of fiscal 2025, HeartSciences reported significant progress in its AI-ECG technology, including FDA submission preparations for the MyoVista® wavECG™ device and the development of the MyoVista Insights™ platform. The company is actively working on regulatory submissions and collaborations to enhance ECG management systems, aiming for a significant commercial opportunity with the CMS 2025 OPPS final rule enabling reimbursement for AI-ECG.

The most recent analyst rating on (HSCS) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.

Spark’s Take on HSCS Stock

According to Spark, TipRanks’ AI Analyst, HSCS is a Underperform.

Heart Test Laboratories, Inc. exhibits significant financial instability, with negative income, high leverage, and poor cash flow generation. Technical indicators remain neutral, failing to show a clear trend. Valuation concerns are substantial, given the negative P/E ratio and lack of dividend yield. Overall, the company’s current financial position presents significant risks to potential investors.

To see Spark’s full report on HSCS stock, click here.

More about Heart Test Laboratories, Inc.

HeartSciences is a medical technology company focused on applying innovative AI-based technology to ECGs (also known as EKGs) to enhance their clinical utility. The company aims to improve healthcare by making ECGs a more valuable cardiac screening tool, particularly in frontline clinical settings. HeartSciences offers a device-agnostic cloud-based solution and a low-cost ECG hardware platform, with one of the largest libraries of AI-ECG algorithms. Their first product candidate for FDA clearance is the MyoVista® wavECG™, designed to provide diagnostic information related to cardiac dysfunction traditionally available only through cardiac imaging.

Average Trading Volume: 13,181

Technical Sentiment Signal: Sell

Current Market Cap: $3.52M

For an in-depth examination of HSCS stock, go to TipRanks’ Stock Analysis page.